» Articles » PMID: 36551852

What Predictability for Animal Models of Peripheral Vestibular Disorders?

Overview
Journal Biomedicines
Date 2022 Dec 23
PMID 36551852
Authors
Affiliations
Soon will be listed here.
Abstract

The different clinical entities grouped under the term peripheral vestibulopathies (PVs) or peripheral vestibular disorders (PVDs) are distinguished mainly based on their symptoms/clinical expression. Today, there are very few commonly accepted functional and biological biomarkers that can confirm or refute whether a vestibular disorder belongs to a precise classification. Consequently, there is currently a severe lack of reliable and commonly accepted clinical endpoints, either to precisely follow the course of the vertigo syndrome of vestibular origin or to assess the benefits of therapeutic approaches, whether they are pharmacological or re-educational. Animal models of PV are a good means to identify biomarkers that could subsequently be exploited in human clinical practice. The question of their predictability is therefore crucial. Ten years ago, we had already raised this question. We revisit this concept today in order to take into account the animal models of peripheral vestibular pathology that have emerged over the last decade, and the new technological approaches available for the behavioral assessment of vestibular syndrome in animals and its progression over time. The questions we address in this review are the following: are animal models of PV predictive of the different types and stages of vestibular pathologies, and if so, to what extent? Are the benefits of the pharmacological or reeducational therapeutic approaches achieved on these different models of PV (in particular the effects of attenuation of the acute vertigo, or acceleration of central compensation) predictive of those expected in the vertiginous patient, and if so, to what extent?

Citing Articles

Molecular profile of vestibular compensation in the medial vestibular nucleus after unilateral labyrinthectomy.

Wang J, Liu D, Tian E, Zhang Y, Guo Z, Chen J J Cell Mol Med. 2024; 28(14):e18532.

PMID: 39039705 PMC: 11263133. DOI: 10.1111/jcmm.18532.


Histaminergic System and Vestibular Function in Normal and Pathological Conditions.

Tighilet B, Trico J, Marouane E, Zwergal A, Chabbert C Curr Neuropharmacol. 2024; 22(11):1826-1845.

PMID: 38504566 PMC: 11284731. DOI: 10.2174/1570159X22666240319123151.


Animal Models of Neurological Disorders: Where Are We Now?.

Panthi S, Ekker M Biomedicines. 2023; 11(5).

PMID: 37238924 PMC: 10216004. DOI: 10.3390/biomedicines11051253.


Pimozide Increases a Delayed Rectifier K Conductance in Chicken Embryo Vestibular Hair Cells.

Giunta R, Cheli G, Spaiardi P, Russo G, Masetto S Biomedicines. 2023; 11(2).

PMID: 36831024 PMC: 9953418. DOI: 10.3390/biomedicines11020488.

References
1.
Rauch S . Vestibular histopathology of the human temporal bone. What can we learn?. Ann N Y Acad Sci. 2001; 942:25-33. DOI: 10.1111/j.1749-6632.2001.tb03732.x. View

2.
Strupp M, Feil K, Dieterich M, Brandt T . Bilateral vestibulopathy. Handb Clin Neurol. 2016; 137:235-40. DOI: 10.1016/B978-0-444-63437-5.00017-0. View

3.
Besnard S, Machado M, Vignaux G, Boulouard M, Coquerel A, Bouet V . Influence of vestibular input on spatial and nonspatial memory and on hippocampal NMDA receptors. Hippocampus. 2011; 22(4):814-26. DOI: 10.1002/hipo.20942. View

4.
Hatat B, Boularand R, Bringuier C, Chanut N, Besnard S, Mueller A . Vertigoheel improves central vestibular compensation after unilateral peripheral vestibulopathy in rats. Front Neurol. 2022; 13:969047. PMC: 9541623. DOI: 10.3389/fneur.2022.969047. View

5.
Rutka J . Aminoglycoside Vestibulotoxicity. Adv Otorhinolaryngol. 2019; 82:101-110. DOI: 10.1159/000490277. View